South America’s drug patent landscape is often treated like a single market—when it’s really a patchwork of rules, timelines, and enforcement realities.
That’s the core takeaway from DrugPatentWatch’s country-by-country breakdown of South American drug…
South American Drug Patents: The Definitive Country-by-Country Breakdown Read Post »
Most 505(b)(2) strategies fail for one reason: they treat the regulatory path like a checklist—not like a competitive weapon.
In the world of CDMOs and specialty labs, 505(b)(2) can look like the “sweet spot”: leverage existing data, potentially shorte…
Combining Lipitor (atorvastatin) with aspirin has been a topic of interest for healthcare professionals due to their common… https://www.Drugchatter.com/chat/18474/what-are-the-effects-of-combining-lipitor-and-aspirin/
DrugChatter: What are the effects of combining lipitor and aspirin? Read Post »
Pharma doesn’t just defend patents anymore—it builds a stack.
In a world where “patent cliffs” are headline events, the more consequential story is happening quietly in the fine print: companies layering exclusivities—NCE (new chemical entity) and orph…
India’s “drug patent clock” is ticking—quietly, legally, and with real consequences for patients, pricing, and innovation.
Most people think patent protection is a simple countdown: file today, exclusivity ends on a fixed date. In practice, India’s dru…
The generic drug race isn’t just about science—it’s about timing, leverage, and a single paragraph.
If you’ve ever wondered why some generic launches feel inevitable while others get delayed for years, the answer is often hiding in plain sight: Hatch-W…
Biopharma’s “Patent Cliff” Isn’t Just a Legal Problem—It’s a Commercial Deadline.
If you’re in biopharma commercial, market access, or vendor services, you already know the story: patents expire, exclusivity fades, and competition arrives faster than m…
Biopharma’s next talent migration isn’t about science—it’s about where the lawsuits are going.
If you want a real-time map of where biopharma careers are headed, don’t start with conferences or job boards. Start with the patent dockets.
A new analysis …
Biosimilar Patent Wars Reveal Exactly Where Biopharma Talent Is Heading Next Read Post »
Specialty pharmacy contracts aren’t just “commercial.” They’re a race against time.
In biopharma, the most valuable window often isn’t the launch date—it’s the months before the drug patent expires. That’s when payers, pharmacy benefit managers (PBMs…
The internet keeps asking: “Can this drug do that?” The pharmacology keeps sighing.
Every few days, a new thread pops up: “If Drug A treats X, why can’t it treat Y?” Or: “If it works for one condition, shouldn’t it work for another?” It’s a question …
Can This Drug…Do That? The internet keeps asking. The pharmacology keeps sighing. Read Post »
Get new actionable insights and updates from BiotechBlog
